On April 2nd, the 5th CGT Asia 2024 Asia Cell and Gene Therapy Innovation Summit, hosted by Tansi Biotechnology, was grandly held in Shanghai. The "CGT Awards CGT Industry Star" 2024 Asia Pacific Cell and Gene Therapy Industry Star Award Ceremony was held at the conference, and Fubio Biotechnology won the "CGT Industry Star 2024 Best CRO" award with its leading technology platform and professional service capabilities.

The "CGT Awards Industry Star 2024 Asia Pacific Cell and Gene Therapy Industry Star Award" is a global award that covers the entire Asia Pacific region's upstream, midstream, downstream, and R&D industries in the field of cell and gene therapy. Its aim is to select outstanding enterprises with strong capabilities and outstanding brand power in the field of cell and gene therapy research and transformation, and promote R&D progress throughout the industry.

This time, Fubio Biotechnology was awarded the title of "CGT Industry Star 2024 Best CRO", fully reflecting the company's outstanding strength in service capabilities, technology platforms, and industry influence, which has been highly recognized by the market.

Fubio Biotechnology is committed to the development and application of gene delivery technology, providing CRO integrated solutions for CGT and IVD fields. We have four core technology platforms covering tool virus production platform, oncolytic virus modification platform, quality control product development platform, and vaccine evaluation product platform, In the future, Fubio Biotechnology will continue to maintain its industry-leading advantages and promote rapid development of the entire industry with better products and services.